<p>啓迪醫療系統（NYSE:INSP - 獲取免費報告）在摩根大通的分析師發佈的報告中，將其目標價格從 67.00 美元下調至 54.00 美元，Benzinga 報道。該券商目前對該股票給予 “中性” 評級。摩根大通的目標價格意味着該股票相較於之前收盤價有 11.94% 的潛在上漲空間。</p>
<ul>
<li>艾利 Lilly 股票上漲：GLP-1 Zepbound 目標睡眠呼吸暫停市場</li>
</ul>
<p>其他幾家券商最近也對 INSP 發表了看法。派珀·桑德勒將啓迪醫療系統的評級從 “增持” 下調至 “中性”，並在週二的研究報告中將其價格目標從 85.00 美元下調至 55.00 美元。扎克斯研究在 4 月 14 日的報告中將啓迪醫療系統的評級從 “強力買入” 下調至 “持有”。加拿大皇家銀行在週二的報告中將啓迪醫療系統的價格目標從 56.00 美元下調至 45.00 美元，並對該股票設定了 “行業表現” 評級。摩根士丹利在 2 月 18 日的報告中對啓迪醫療系統設定了 60.00 美元的目標價格。最後，Truist Financial 在週二的報告中將啓迪醫療系統的股票價格目標從 64.00 美元下調至 50.00 美元，並對該股票設定了 “持有” 評級。四位分析師對該股票給予了買入評級，十五位分析師給予了持有評級，一位分析師給予了賣出評級。根據 MarketBeat.com 的數據，該股票的共識評級為 “持有”，共識目標價格為 85.00 美元。</p>
<p><strong>閲讀我們最新的 INSP 股票分析</strong></p>
<h2>啓迪醫療系統價格表現</h2>
<ul>
<li>啓迪醫療上漲 15% 後突破，分析師稱其為買入</li>
</ul>
<p>在週二的交易中，INSP 下跌 6.60 美元，報 48.24 美元。該股票的交易量為 4,487,559 股，而其平均交易量為 1,214,082 股。該公司的 50 日移動平均價格為 56.73 美元，200 日移動平均價格為 79.64 美元。該公司的市值為 13.9 億美元，市盈率為 9.69，市盈增長比率為 2.92，貝塔值為 0.83。啓迪醫療系統的年內最低價為 44.41 美元，年內最高價為 163.35 美元。</p>
<p>啓迪醫療系統（NYSE:INSP - 獲取免費報告）最後一次發佈財報是在 5 月 4 日，週一。該公司報告每股收益為 0.10 美元，超出分析師共識預期的（0.28 美元）0.38 美元。啓迪醫療系統的股本回報率為 10.96%，淨利潤率為 15.95%。該公司在該季度的收入為 2.0458 億美元，而共識預期為 2.0004 億美元。在去年同期，該公司每股收益為 0.10 美元。與去年同期相比，該公司的收入增長了 1.6%。啓迪醫療系統將其 2026 財年的指導目標設定為 0.750-1.250 美元每股收益。作為一個整體，賣方分析師預測啓迪醫療系統在當前財年將發佈 1.82 美元的每股收益。</p>
<h2>啓迪醫療系統的機構交易</h2>
<ul>
<li>小型股是否預示市場下跌？</li>
</ul>
<p>對該公司的對沖基金最近對其持倉進行了調整。CWM LLC 在第四季度將其在啓迪醫療系統的股份增加了 216.1%。CWM LLC 現在擁有 354 股該公司的股票，價值 33,000 美元，此前在該期間又購買了 242 股。Havemeyer Place LP 在第四季度購買了啓迪醫療系統的新股份，價值 39,000 美元。V Square Quantitative Management LLC 在第四季度購買了啓迪醫療系統的新股份，價值 40,000 美元。Manning &amp; Napier Advisors LLC 在第三季度購買了啓迪醫療系統的新股份，價值 32,000 美元。最後，Smartleaf Asset Management LLC 在第四季度將其在啓迪醫療系統的股份增加了 84.0%。Smartleaf Asset Management LLC 現在擁有 449 股該公司的股票，價值 42,000 美元，此前在該期間又購買了 205 股。94.91% 的股票目前由機構投資者持有。</p>
<h2>啓迪醫療系統新聞摘要</h2>
<p>以下是本週影響啓迪醫療系統的主要新聞：</p>
<ul>
<li>積極情緒：第一季度業績超出預期——啓迪報告每股收益 0.10 美元，收入 2.046 億美元，超出共識並顯示出適度的同比增長；該公司還發布了季度材料和幻燈片。閲讀更多。</li>
<li>積極情緒：一些公司仍持建設性態度——儘管目標被下調，Stifel 和 Mizuho 仍保持買入/跑贏大盤的立場（目標價格下調），表明一些分析師仍然看到低估值的上漲空間。閲讀更多。</li>
<li>中性情緒：完整的財報電話會議記錄和幻燈片可供詳細查看——投資者可以查看管理層對編碼、報銷時機和 WISeR 計劃影響的解釋。閲讀更多。</li>
<li>消極情緒：大幅下調 2026 財年指導——管理層現在預計每股收益為 0.75–1.25 美元，收入為 8.25 億–8.75 億美元，而市場預期接近每股收益 1.99 美元和收入約 9.61 億美元，這一大幅下調的前景引發了投資者的擔憂。閲讀更多。</li>
<li>消極情緒：提到報銷和 WISeR 計劃的干擾——管理層表示，編碼/報銷時機和與 WISeR 相關的執行問題正在減少 2026 年的手術量，這是較弱指導的主要運營原因。閲讀更多。</li>
<li>消極情緒：多位分析師下調目標價格和評級——幾家券商下調了目標（Truist、富國銀行、貝爾德）或轉為中性/持有，指導失誤後增加了賣壓。閲讀更多。</li>
</ul>
<h2>啓迪醫療系統公司簡介</h2>
<p>（獲取免費報告）</p>
<p>啓迪醫療系統公司是一家醫療科技公司，專注於用於治療阻塞性睡眠呼吸暫停（OSA）的可植入神經刺激設備。該公司的旗艦產品啓迪®系統，通過對舌下神經的定向刺激，在睡眠期間保持氣道通暢，為對持續正壓呼吸機（CPAP）設備不耐受或管理不當的患者提供了一種替代療法。</p>
<p>啓迪系統由一個可植入的脈衝發生器、一個監測呼吸模式的傳感導線和一個激活舌下神經的刺激導線組成。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們認為比啓迪醫療系統更好的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUlOU1A?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUlOU1A"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 到啓迪醫療系統嗎？</h2>
<p>在你考慮啓迪醫療系統之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而啓迪醫療系統並不在名單上。</p>
<p>雖然啓迪醫療系統目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

啟迪醫療

摩根大通

標普健康醫療設備 ETF - SPDR

美國醫藥設備 ETF - iShares

醫藥突破 ETF - ALPS

<p>摩根大通已將啓迪醫療（NYSE:INSP）的目標股價從 67.00 美元下調至 54.00 美元，維持 “中性” 評級。這一調整表明該股相較於前一交易日收盤價有 11.94% 的潛在上漲空間。其他券商也對其評級進行了調整，Piper Sandler 和 Zacks Research 下調了他們的評估。儘管發生了這些變化，仍有四位分析師將該股評級為買入，而共識評級保持為持有，目標價為 85.00 美元。啓迪醫療最近公佈的財報超出預期，顯示出適度的收入增長</p>

<p>Inspire Medical Systems (NYSE:INSP - Get Free Report) had its target price lowered by stock analysts at JPMorgan Chase &amp; Co. from $67.00 to $54.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has a &#34;neutral&#34; rating on the stock. JPMorgan Chase &amp; Co.'s target price would indicate a potential upside of 11.94% from the stock's previous close.</p>
<div class="lb-trans"><p>啓迪醫療系統（NYSE:INSP - 獲取免費報告）在摩根大通的分析師發佈的報告中，將其目標價格從 67.00 美元下調至 54.00 美元，Benzinga 報道。該券商目前對該股票給予 “中性” 評級。摩根大通的目標價格意味着該股票相較於之前收盤價有 11.94% 的潛在上漲空間。</p>
</div><ul>
<li>Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market</li>
</ul>
<div class="lb-trans"><ul>
<li>艾利 Lilly 股票上漲：GLP-1 Zepbound 目標睡眠呼吸暫停市場</li>
</ul>
</div><p>Several other brokerages have also recently weighed in on INSP. Piper Sandler cut Inspire Medical Systems from an &#34;overweight&#34; rating to a &#34;neutral&#34; rating and decreased their price target for the company from $85.00 to $55.00 in a research note on Tuesday. Zacks Research lowered Inspire Medical Systems from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, April 14th. Royal Bank Of Canada cut their price target on Inspire Medical Systems from $56.00 to $45.00 and set a &#34;sector perform&#34; rating on the stock in a report on Tuesday. Morgan Stanley set a $60.00 target price on Inspire Medical Systems in a report on Wednesday, February 18th. Finally, Truist Financial cut their price target on shares of Inspire Medical Systems from $64.00 to $50.00 and set a &#34;hold&#34; rating on the stock in a report on Tuesday. Four analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of &#34;Hold&#34; and a consensus target price of $85.00.</p>
<div class="lb-trans"><p>其他幾家券商最近也對 INSP 發表了看法。派珀·桑德勒將啓迪醫療系統的評級從 “增持” 下調至 “中性”，並在週二的研究報告中將其價格目標從 85.00 美元下調至 55.00 美元。扎克斯研究在 4 月 14 日的報告中將啓迪醫療系統的評級從 “強力買入” 下調至 “持有”。加拿大皇家銀行在週二的報告中將啓迪醫療系統的價格目標從 56.00 美元下調至 45.00 美元，並對該股票設定了 “行業表現” 評級。摩根士丹利在 2 月 18 日的報告中對啓迪醫療系統設定了 60.00 美元的目標價格。最後，Truist Financial 在週二的報告中將啓迪醫療系統的股票價格目標從 64.00 美元下調至 50.00 美元，並對該股票設定了 “持有” 評級。四位分析師對該股票給予了買入評級，十五位分析師給予了持有評級，一位分析師給予了賣出評級。根據 MarketBeat.com 的數據，該股票的共識評級為 “持有”，共識目標價格為 85.00 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on INSP</strong></p>
<div class="lb-trans"><p><strong>閲讀我們最新的 INSP 股票分析</strong></p>
</div><h2>Inspire Medical Systems Price Performance</h2>
<div class="lb-trans"><h2>啓迪醫療系統價格表現</h2>
</div><ul>
<li>Inspire Medical Up 15% After Breakout, Analysts Say It's A Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>啓迪醫療上漲 15% 後突破，分析師稱其為買入</li>
</ul>
</div><p>INSP traded down $6.60 during trading on Tuesday, hitting $48.24. The stock had a trading volume of 4,487,559 shares, compared to its average volume of 1,214,082. The company has a 50 day moving average price of $56.73 and a 200-day moving average price of $79.64. The firm has a market cap of $1.39 billion, a price-to-earnings ratio of 9.69, a P/E/G ratio of 2.92 and a beta of 0.83. Inspire Medical Systems has a one year low of $44.41 and a one year high of $163.35.</p>
<div class="lb-trans"><p>在週二的交易中，INSP 下跌 6.60 美元，報 48.24 美元。該股票的交易量為 4,487,559 股，而其平均交易量為 1,214,082 股。該公司的 50 日移動平均價格為 56.73 美元，200 日移動平均價格為 79.64 美元。該公司的市值為 13.9 億美元，市盈率為 9.69，市盈增長比率為 2.92，貝塔值為 0.83。啓迪醫療系統的年內最低價為 44.41 美元，年內最高價為 163.35 美元。</p>
</div><p>Inspire Medical Systems (NYSE:INSP - Get Free Report) last released its earnings results on Monday, May 4th. The company reported $0.10 earnings per share for the quarter, beating analysts' consensus estimates of ($0.28) by $0.38. Inspire Medical Systems had a return on equity of 10.96% and a net margin of 15.95%.The firm had revenue of $204.58 million during the quarter, compared to the consensus estimate of $200.04 million. During the same period in the prior year, the company posted $0.10 EPS. The company's revenue was up 1.6% compared to the same quarter last year. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. As a group, sell-side analysts predict that Inspire Medical Systems will post 1.82 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>啓迪醫療系統（NYSE:INSP - 獲取免費報告）最後一次發佈財報是在 5 月 4 日，週一。該公司報告每股收益為 0.10 美元，超出分析師共識預期的（0.28 美元）0.38 美元。啓迪醫療系統的股本回報率為 10.96%，淨利潤率為 15.95%。該公司在該季度的收入為 2.0458 億美元，而共識預期為 2.0004 億美元。在去年同期，該公司每股收益為 0.10 美元。與去年同期相比，該公司的收入增長了 1.6%。啓迪醫療系統將其 2026 財年的指導目標設定為 0.750-1.250 美元每股收益。作為一個整體，賣方分析師預測啓迪醫療系統在當前財年將發佈 1.82 美元的每股收益。</p>
</div><h2>Institutional Trading of Inspire Medical Systems</h2>
<div class="lb-trans"><h2>啓迪醫療系統的機構交易</h2>
</div><ul>
<li>Are Small Caps a Harbinger of Market Declines?</li>
</ul>
<div class="lb-trans"><ul>
<li>小型股是否預示市場下跌？</li>
</ul>
</div><p>Hedge funds have recently made changes to their positions in the company. CWM LLC raised its stake in shares of Inspire Medical Systems by 216.1% in the fourth quarter. CWM LLC now owns 354 shares of the company's stock valued at $33,000 after buying an additional 242 shares during the period. Havemeyer Place LP bought a new stake in shares of Inspire Medical Systems in the fourth quarter valued at $39,000. V Square Quantitative Management LLC bought a new stake in shares of Inspire Medical Systems in the fourth quarter valued at $40,000. Manning &amp; Napier Advisors LLC bought a new stake in shares of Inspire Medical Systems in the third quarter valued at $32,000. Finally, Smartleaf Asset Management LLC raised its stake in shares of Inspire Medical Systems by 84.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 449 shares of the company's stock valued at $42,000 after buying an additional 205 shares during the period. 94.91% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>對該公司的對沖基金最近對其持倉進行了調整。CWM LLC 在第四季度將其在啓迪醫療系統的股份增加了 216.1%。CWM LLC 現在擁有 354 股該公司的股票，價值 33,000 美元，此前在該期間又購買了 242 股。Havemeyer Place LP 在第四季度購買了啓迪醫療系統的新股份，價值 39,000 美元。V Square Quantitative Management LLC 在第四季度購買了啓迪醫療系統的新股份，價值 40,000 美元。Manning &amp; Napier Advisors LLC 在第三季度購買了啓迪醫療系統的新股份，價值 32,000 美元。最後，Smartleaf Asset Management LLC 在第四季度將其在啓迪醫療系統的股份增加了 84.0%。Smartleaf Asset Management LLC 現在擁有 449 股該公司的股票，價值 42,000 美元，此前在該期間又購買了 205 股。94.91% 的股票目前由機構投資者持有。</p>
</div><h2>Inspire Medical Systems News Summary</h2>
<div class="lb-trans"><h2>啓迪醫療系統新聞摘要</h2>
</div><p>Here are the key news stories impacting Inspire Medical Systems this week:</p>
<div class="lb-trans"><p>以下是本週影響啓迪醫療系統的主要新聞：</p>
</div><ul>
<li>Positive Sentiment: Q1 results beat estimates — Inspire reported $0.10 EPS and $204.6M in revenue, topping consensus and showing modest year‑over‑year growth; the company also released its quarter materials and slide deck. Read More.</li>
<li>Positive Sentiment: Some firms remain constructive — despite cuts to targets, Stifel and Mizuho kept buy/outperform stances (with lower price targets), indicating some analysts still see upside at lower valuations. Read More.</li>
<li>Neutral Sentiment: Full earnings call transcript and slide deck are available for detail — investors can review management’s explanations on coding, reimbursement timing and WISeR program impacts. Read More.</li>
<li>Negative Sentiment: Large FY‑2026 guidance cut — management now expects $0.75–$1.25 EPS and $825M–$875M revenue vs. street expectations near $1.99 EPS and ~$961M revenue, a materially lower outlook that drove investor concern. Read More.</li>
<li>Negative Sentiment: Reimbursement and WISeR program disruptions cited — management said coding/reimbursement timing and WISeR-related execution issues are reducing procedure volumes in 2026, the main operational reason for the weaker guidance. Read More.</li>
<li>Negative Sentiment: Multiple analyst price‑target cuts and rating shifts — several brokers trimmed targets (Truist, Wells Fargo, Baird) or moved to neutral/hold, increasing selling pressure after the guidance miss. Read More.</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：第一季度業績超出預期——啓迪報告每股收益 0.10 美元，收入 2.046 億美元，超出共識並顯示出適度的同比增長；該公司還發布了季度材料和幻燈片。閲讀更多。</li>
<li>積極情緒：一些公司仍持建設性態度——儘管目標被下調，Stifel 和 Mizuho 仍保持買入/跑贏大盤的立場（目標價格下調），表明一些分析師仍然看到低估值的上漲空間。閲讀更多。</li>
<li>中性情緒：完整的財報電話會議記錄和幻燈片可供詳細查看——投資者可以查看管理層對編碼、報銷時機和 WISeR 計劃影響的解釋。閲讀更多。</li>
<li>消極情緒：大幅下調 2026 財年指導——管理層現在預計每股收益為 0.75–1.25 美元，收入為 8.25 億–8.75 億美元，而市場預期接近每股收益 1.99 美元和收入約 9.61 億美元，這一大幅下調的前景引發了投資者的擔憂。閲讀更多。</li>
<li>消極情緒：提到報銷和 WISeR 計劃的干擾——管理層表示，編碼/報銷時機和與 WISeR 相關的執行問題正在減少 2026 年的手術量，這是較弱指導的主要運營原因。閲讀更多。</li>
<li>消極情緒：多位分析師下調目標價格和評級——幾家券商下調了目標（Truist、富國銀行、貝爾德）或轉為中性/持有，指導失誤後增加了賣壓。閲讀更多。</li>
</ul>
</div><h2>Inspire Medical Systems Company Profile</h2>
<div class="lb-trans"><h2>啓迪醫療系統公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company's flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.</p>
<div class="lb-trans"><p>啓迪醫療系統公司是一家醫療科技公司，專注於用於治療阻塞性睡眠呼吸暫停（OSA）的可植入神經刺激設備。該公司的旗艦產品啓迪®系統，通過對舌下神經的定向刺激，在睡眠期間保持氣道通暢，為對持續正壓呼吸機（CPAP）設備不耐受或管理不當的患者提供了一種替代療法。</p>
</div><p>The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.</p>
<div class="lb-trans"><p>啓迪系統由一個可植入的脈衝發生器、一個監測呼吸模式的傳感導線和一個激活舌下神經的刺激導線組成。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Inspire Medical Systems</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比啓迪醫療系統更好的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUlOU1A" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=INSP"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Inspire Medical Systems Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 到啓迪醫療系統嗎？</h2>
</div><p>Before you consider Inspire Medical Systems, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮啓迪醫療系統之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inspire Medical Systems wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而啓迪醫療系統並不在名單上。</p>
</div><p>While Inspire Medical Systems currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然啓迪醫療系統目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

JPMorgan Chase & Co. Cuts Inspire Medical Systems (NYSE:INSP) Price Target to $54.00

Market Beat

Defiance Daily Target 2X Long JPM ETF

禮來

Piper Sandler Cos

Zacks Quality International ETF

Zacks Focus Growth ETF

Zacks Small/Mid Cap ETF

Nano Labs

加拿大皇家銀行

蒙特利爾銀行

加拿大帝國商業銀行

摩根士丹利

Truist Financial

K Wave Media

Cushman & Wakefield

SEAPEAK LLC 9% CUM RED PERP PREF UNITS SER A

Childrens Place

Harvard Ave Acquisition - Unit

Medley, Inc.

QuantumScape

Quantum-Si

Squarex Pharmaceutical Corp

曼哈頓聯合軟件

Hennessy Advisors

Brown Advisory US Smaller Companies PLC GBP

F&C Asset Management PLC

Arcadian Asset

Liontrust Asset Management PLC

Stifel Financial

瑞穗金融集團

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

K WAVE MEDIA LTD C/WTS 14/05/2030(TO PUR COM)

SEAPEAK LLC 8.5% CUM RED PERP PFD UNTS FXD FLT SER B

Quantum - Si - CW27

Hennessy Advisors Pref Share HNNAZ 4.875 12/31/26

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

Mizuho Financial Group, Inc.

摩根大通將啓迪醫療系統（NYSE:INSP）的目標價下調至 54.00 美元